Jazz Pharmaceuticals
 | |
| Company type | Private |
|---|---|
| Nasdaq: JAZZ | |
| Industry | Biotechnology |
| Headquarters | Dublin, Ireland |
Key people | Bruce C. Cozadd (Chairman and CEO) Kathryn E. Falberg (CFO and Executive Vice President) Suzanne Sawochka Hooper (Executive Vice President and General Counsel) Russell J. Cox (Chief Commercial Officer) and Executive Vice President) |
| Products | Xyrem, FazaClo, FazaClo HD, Luvox CR, Prialt |
| Revenue |  $340.9 million Q3 2015[1] |
| $159.3 million Q3 2015[1] | |
| Website | www |
Jazz Pharmaceuticals PLC (a merger of Jazz Pharmaceuticals and Azur Pharma PLC) is an Ireland-based biopharmaceutical company which specializes of identifying, developing and commercializing pharmaceutical products. It was founded in 2003.[2] One of the company's most significant products is the United States Food and Drug Administration (FDA) approved drug, Xyrem (Sodium Oxybate - another term for the identical substance more commonly referred to as GHB Gamma Hydroxy Butrate).
In 2007, the company pled guilty to felony charges related to its illegal marketing of Xyrem for off-label use.[3]
The company is also a member of the Pharmaceutical Research and Manufacturers of America (PhRMA).[4]
Company history & Acquisitions
2010
On February 18, the FDA accepted a new drug application for JZP-6 (Sodium Oxybate) for the treatment of Fibromyalgia[5] In the following December, a new patent was issued for Sodium Oxybate [6]
2011
On September 19, Jazz Pharmaceuticals and Azur Pharma PLC agreed to merge[7]
2012
On April 26, the company acquired EUSA Pharma for $650 million (plus $50 million in milestone payments[8] In September the company successfully sold its Women's Health business to Meda for $95 million [9] In December, the company began clinical trial of intravenous Erwinaze in patients suffering from Acute Lymphoblastic Leukemia [10]
2014
In January, the company announced it would acquire the rare disease drug developer Gentium SpA and its lead product Defitelio for $1 billion[11][12]
2016
In May, the company announced it would acquire Alizé Pharma II for $20.5 million.[13] At the end of the same month, the company announced its largest acquisition to date, with the purchase of Celator Pharmaceuticals for $1.5 billion.[14]
Acquisition history
The following is an illustration of the company's major mergers and acquisitions and historical predecessors (this is not a comprehensive list):
| Jazz Pharmaceuticals |
| |||||||||||||||||||||||||||||||||||||||||||||
References
- ^ a b Jazz Pharmaceuticals (9 November 2015). "Jazz Pharmaceuticals Announces Third Quarter 2015 Financial Results". prnewswire.com.
- ^ "History". Jazz Pharmaceuticals. Retrieved 22 November 2016.
- ^ "Jazz Pharmaceuticals, Inc. Agrees to Pay $20 Million to Resolve Criminal and Civil Allegations in "Off-label" Marketing Investigation".
- ^ http://www.fiercepharma.com/pharma/teva-wins-controversial-phrma-bid-despite-protests-from-branded-rivals
- ^ "Jazz Pharmaceuticals - Investor & Media - Press Release". jazzpharma.com.
- ^ "Jazz Pharmaceuticals - Investor & Media - Press Release". jazzpharma.com.
- ^ "Jazz Pharmaceuticals - Investor & Media - Press Release". jazzpharma.com.
- ^ "Jazz Pharmaceuticals - Investor & Media - Press Release". jazzpharma.com.
- ^ "Jazz Pharmaceuticals - Investor & Media - Press Release". jazzpharma.com.
- ^ "Jazz Pharmaceuticals - Investor & Media - Press Release". jazzpharma.com.
- ^ Armstrong, Drew (December 19, 2013). "Jazz to Buy Gentium for $1 Billion for Rare-Disease Drugs". Bloomberg News.
- ^ "Jazz Pharma Acquiring Gentium for $1B". Gen. Eng. Biotechnol. News. Vol. 34, no. 2. January 15, 2014. p. 10.
{{cite news}}:|format=requires|url=(help) - ^ "Alizé Pharma II Acquired by Jazz Pharmaceuticals for Up to $20.5M - GEN News Highlights - GEN".
- ^ "Jazz Pharmaceuticals to Acquire Celator for $1.5B - GEN News Highlights - GEN".